DARE Emboldened, IFRX On Track, APRI Awaits FDA Word, Watch Out For DYNT

Dar‚ Bioscience Inc. (DARE) gained 50% to close Monday's trading at $2.79. The Company has entered into an agreement to license SST-6007, a potential treatment for Female Sexual Arousal Disorder, from Strategic Science & Technologies LLC. A phase 2b clinical trial of SST-6007 is expected to be initiated in the second half of 2018.

from RTT - Biotech http://ift.tt/2ChtOPU
via IFTTT